Magnesium Sulfate Torbay Pharmaceuticals (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that act as calcium antagonists, stabilising cell membranes, reducing calcium influx, and decreasing neuromuscular excitability. This action helps prevent seizures, correct electrolyte imbalances, and stabilise cardiac electrical activity.

The dose of magnesium sulfate is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical response. Dosage regimens are individualized and should follow local treatment guidelines.

Magnesium sulfate is commonly used in obstetric care for eclampsia prevention, but its safety profile in pregnancy is classified as unknown in some regions. It should only be used when clearly indicated and under medical supervision. Limited data are available for breastfeeding, so clinical judgment is required.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Compared with other electrolytes such as calcium gluconate or potassium chloride, magnesium sulfate uniquely provides calcium antagonism and neuromuscular stabilization, making it the preferred choice for seizure prophylaxis in pre‑eclampsia and for certain cardiac arrhythmias. Its profile differs in indications and side‑effect spectrum.

Magnesium Sulfate Torbay Pharmaceuticals is supplied as a sterile solution for injection. Store it at 2‑8 °C, keep the vial refrigerated, protect from light, and avoid freezing or shaking. Use aseptic technique when preparing for administration.

The product is administered by intramuscular or intravenous injection. The route, rate of infusion, and concentration are selected by the prescriber according to the clinical indication and patient condition, following standard aseptic procedures.

Serious risks include respiratory depression, severe hypotension, cardiac arrest, hypermagnesemia leading to muscle weakness or paralysis, and neuromuscular blockade. Continuous monitoring of vital signs and serum magnesium levels is essential during high‑dose or prolonged therapy.

Magnesium sulfate should be avoided in patients with known hypersensitivity to magnesium salts, severe renal failure without dialysis, existing heart block or severe conduction disturbances, and in those receiving high doses of other magnesium‑containing products unless closely monitored.